Monday, December 19, 2011
Advaxis Inc., of Princeton, N.J., said preliminary data from a Phase II trial of ADXS-HPV, with or without cisplatin, in Indian women with recurrent/refractory cervical cancer, showed no serious adverse events. The primary endpoint is overall survival and, though early in the trial, clinical responses have been seen alone or in combination with chemotherapy and have included one complete reponse and three partial responses.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.